A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients

Part of paid clinical trials in Glendale, California.

Sponsor
Teligene US
Study ID
NCT06010342
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Solid Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • TL118 Capsule — DRUG
    Oral administration

Study Details

The main objective of the study will be to evaluate the efficacy of TL118 in participants with solid tumors harboring NTRK gene fusions

Key Dates

Start date
Mar 16, 2023
Status verified
Apr 2026
Primary completion
Dec 31, 2027
Completion
Dec 31, 2028

Study Design

Enrollment
60 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Single arm, Open label
    Participants will receive TL118 capsule taken orally with (preferred) or without food, 252 mg twice daily, 28 days for a cycle.

Primary Outcome Measure

Objective Response Rate (ORR) [ Time Frame: Pre-dose up to approximately 24 months post-dose ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
Adventist Health GlendaleGlendaleCalifornia91206-
Texas OncologyDallasTexas75251-
The University of Texas MD Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Glendale, CA

By research site
Adventist Health Glendale· Glendale, CATexas Oncology· Dallas, TXThe University of Texas MD Anderson Cancer Center· Houston, TX

Related Studies